ArticleNeuro-oncology2026
Metabolic profiling defines glioblastoma subtypes with distinct prognoses and therapeutic vulnerabilities.
Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a highly aggressive brain tumor with profound metabolic heterogeneity. However, a clinically actionable classification based on metabolic gene expression remains undefined.
methodsWe conducted a comprehensive multi-omics analysis of IDH-wildtype GBMs from three publicly available datasets. Prognostic metabolism-related genes were used to define transcriptional subtypes, which were validated in independent datasets and patient-derived cell (PDC) models. Functional assays and drug sensitivity studies were performed to explore therapeutic relevance.
resultsWe identified three distinct metabolic subtypes: M1, enriched for synaptic signaling and amino acid metabolism, exhibited leading-edge anatomical features; M2, characterized by mitochondrial metabolism and cell cycle activity, was associated with favorable survival; and M3, marked by hypoxia, immune activation and suppression, and broad metabolic pathway engagement, correlated with poor prognosis. These subtypes were reproducible across cohorts and faithfully recapitulated in PDC models. Metabolomic profiling confirmed distinct subtype-specific metabolic signatures. Notably, M3 cells showed high sensitivity to inhibitors targeting glycosaminoglycan degradation, nicotinamide metabolism, and retinoic acid pathways in both in vitro and in vivo models.
conclusionOur study defines three biologically and clinically relevant metabolic subtypes of IDH-wildtype GBM. This classification reveals distinct metabolic programs and therapeutic vulnerabilities, providing a framework for precision metabolism-targeted strategies in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.